- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
SPARC has shifted strategic focus to oncology and immunology. Key R&D assets advanced: SCD-153 (Alopecia Areata) entered Phase 1b, while SBO-154 (cancer ADC) received a "study may proceed" from USFDA, with an IND also filed in India. Setbacks include pausing Vodobatinib’s Parkinson's development and Vibozilimod studies missing primary endpoints. Consolidated loss improved to ₹342.51 Cr from ₹387.21 Cr, with revenue at ₹71.77 Cr. To support future growth, the company plans to increase its credit line to ₹550 Cr and seeks approval to raise up to ₹1,800 Cr.
All announcements from Sun Pharma Advanced Research Company Limited